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Abstract
Background: Susac’s Syndrome (SS) consists of the triad of encephalopathy, branch retinal artery occlusions (BRAO)
and hearing loss (HL). Histopathologically, SS is characterised by a microangiopathy, and some observations suggest
that an immune-mediated damage of endothelial cells might play a role. These findings also implicate a similarity
between SS and other autoimmune diseases, most notably juvenile dermatomyositis (JDM). However, SS and JDM are
commonly thought to affect distinct and non-overlapping sets of organs, and it is currently not clear how these
specificities arise. Moreover, in the absence of clinical trials, some authors suggest that therapeutic approaches in SS
should rely on the model of other autoimmune diseases such as JDM.
Case presentation: Here, we report a case of SS in a 32-year-old pregnant woman. She initially was admitted to the
hospital with subacute severe encephalopathy and multifocal neurologic signs. As cranial magnetic resonance
imaging (MRI) revealed multifocal white matter lesions including the corpus callosum, erroneously a diagnosis of
multiple sclerosis (MS) was made, and intravenous methylprednisolone (IVMP) therapy was initiated. A few days later,
an exanthema appeared on the trunk and extremities, which was diagnosed as livedo racemosa (LR). Several weeks
later, the patient was readmitted to the clinic with an obscuration of her left visual hemifield and a bilateral HL.
Ophthalmologic examination revealed extensive ischemic damage to both retinae. Now the correct diagnosis of SS
was established, based on the above triad of clinical symptoms in conjunction with typical MRI and fundoscopic
findings. When SS was diagnosed, the standard therapy with intravenous cyclophosphamide (IVCTX) was not
instituted because of a significant risk of permanent infertility. Instead, sustained control of disease activity could be
achieved with a therapeutic regime combining prednisolone, intravenous immunoglobulins (IVIG), mycophenylate
mofetil (MM), and methotrexate (MTX).
Conclusions: An association with LR has only been described in very few cases of SS before and further underlines
the pathogenetic relationship between SS and other autoimmune diseases such as JDM. In young women with SS
and the desire for a child the combination of MM and MTX may represent a reasonable alternative to IVCTX.
Background
SS consists of the triad of encephalopathy, BRAO and HL
[1,2]. The clinical presentation is highly variable. In par-
ticular, any of the above symptoms can occur first and
dominate the clinical picture [2-4]. Accordingly, it has
been proposed to distinguish between an encephalopathic
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form of SS and a recurrent BRAO subset [5]. Between
the two, the former is typically more severe and shows
a monophasic clinical course over a period of usually no
longer than two years, during which disease activity may
fluctuate widely. In MRI SS is associated with a number
of rather specific signs including snowball- and spoke-like
lesions on sagittal images, which correspond to microin-
farcts in the centre of the corpus callosum and are deemed
pathognomonic of SS [5,6]. More recently, MRI at 7 Tesla
has been shown to permit a better differentiation between
white matter lesions in SS and those in MS [7].
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Histopathologically, SS is associated with a microan-
giopathy of the brain, retina and cochlea [1,3,4]. Although
a detailed pathomechanism remains to be elucidated,
antibody-mediated damage of endothelial cells is dis-
cussed as an important step. This includes the demon-
stration of activated complement components in the
capillaries of SS brain biopsies [8,9]. Moreover, anti-
endothelial cell antibodies (AECA) of the IgG variety have
been described in the serum of patients with SS [9,10].
Although the exact specificity of these antibodies is still
unknown, they have been shown to recognize a distinc-
tive protein of 50 kDa in Western blotting which is not
bound by AECA of other autoimmune diseases, includ-
ing dermatomyositis (DM) [9]. More generally, the notion
of an immunopathogenesis of SS is supported by the
typical inflammatory constellation in cerebrospinal fluid
(CSF) studies and the response to immunosuppressive
treatment.
Indeed, SS is in principle amenable to immunosuppres-
sive therapy, although in some cases disease activity has
proven difficult to control [8]. Due to the absence of clin-
ical trials, therapeutic approaches are largely based on
anecdotal reports and on models of other autoimmune
diseases, most notably JDM. Therapeutic regimes usually
rely on a combination of corticosteroids and IVIG over an
extended period of time (minimum 6 months). In more
severe cases, an additional immunosuppressive therapy
is recommended, preferably in the form of IVCTX pulse
therapy. The combination of MM and MTX is considered
an alternative, but is usually reserved for cases with less
threatening disease [8].
Here, we report a case of SS that initially presented
with acute encephalopathy and LR. This at first directed
diagnostic considerations towards systemic lupus erythe-
matosus (SLE) or a primary vasculitis syndrome, and the
correct diagnosis of SS was established only several weeks
later when the full clinical triad became manifest. Because
of a risk of permanent infertility the standard immunosup-
pressive therapy with IVCTX was not given, but sustained
control of disease activity was achieved with a combina-
tion of IVIG, MM and MTX. Our case illustrates that
SS should always be considered as a differential diagno-
sis in a patient with acute encephalopathy, especially in
the presence of additional skin manifestations, and that a
therapeutic regime without CTX may be effective even in
some patients with an aggressive course of the disease.
Case presentation
A 32-year-old woman of European descent was in week
32 of her first, uncomplicated pregnancy when a sub-
tle change in personality including a neglect of her daily
duties was noticed. One week later, while on a holiday
in Austria, she developed an unsteadiness of gait and
slurred speech and was admitted to the hospital. Clinical
examination revealed dysarthria and a hemispasticity with
positive Babinski sign on the left side. While neuropsy-
chologically still adequate on the evening of admission,
she became severely confused and disoriented overnight.
She did not complain of headaches at any time. Cranial
MRI showed multiple small T2-intense lesions in both
supra- and infratentorial locations, some of which exhib-
ited diffusion restriction. Several lesions were found in the
corpus callosum. CSF examination demonstrated a mild
lymphocytic pleocytosis (13 cells/μl) and a markedly ele-
vated protein concentration (1,800 mg/l) in the absence
of oligoclonal bands. Otherwise, routine laboratory tests
were normal. She delivered her child by emergency cae-
sarean section and received antiviral therapy until nega-
tive results of virus PCR arrived. An extensive serological
diagnostic did not yield evidence of viral, bacterial or
protozoal infection. A diagnosis of MS was made, and
a pulse of IVMP was given (5 × 500mg). Several days
after completion of IVMP therapy an exanthema appeared
on the trunk and extremities, which was diagnosed as
LR by a consultant dermatologist. A therapy with oral
prednisolone was initiated, under which the exanthema
resolved quickly and neurological symptoms improved
gradually.
Due to a misunderstanding, medication was not contin-
ued upon discharge from hospital. Two days later, having
returned to Germany, the patient again became severely
confused and apathetic and was admitted to our clinic. On
neurological examination, she had an ataxic stance and
gait, dysmetria, dysarthria and bilaterally hyperactive ten-
don reflexes. MRI demonstrated several small T2-intense
lesions, some of which showed contrast enhancement and
others diffusion restriction (Figure 1a-e). Some lesions
were located in the centre of the corpus callosum or
connected to its roof (Figure 1c). Overall, the corpus
callosum appeared atrophic (Figure 1d). Since cerebral
vasculitis was considered a differential diagnosis, a digital
subtraction angiography was performed, but was unre-
markable. Laboratory tests for anti-nuclear antibodies,
anti-neutrophil cytoplasmic antibodies, anti-thyroid, anti-
neuronal and paraneoplastic antibodies, viral hepatitis
and human immunodeficiency virus were all negative.
There was also no evidence of antiphospholipid antibod-
ies, lupus anticoagulant or inherited thrombophilia. On
admission, a bluish, net-like exanthema on the trunk and
legs was noticed and diagnosed as LR. Biopsy confor-
mation was attempted, but when a punch biopsy was
performed two days after the start of another IVMP pulse
(5 × 500mg), the skin changes had almost vanished and
the biopsy showed normal dermis. A therapy with oral
prednisolone was re-initiated, and cognitive deficits and
gait disorder gradually improved.
Six weeks later (when prednisolone had been tapered
to 40 mg/d) the patient was readmitted to our clinic. She
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Figure 1MRI, DSA and funduscopic studies. a) Axial fluid-attenuated inversion recovery image showing multiple small white matter lesions.
b) Diffusion-weighted image with multiple small lesions exhibiting diffusion restriction (arrows) and correspondingly decreased ADC values (not
shown). c) Sagittal T2 image showing centrally located corpus callosum lesions (arrow) and one lesion with spoke-like morphology (tailed arrow).
d) Near-median sagittal T2 image demonstrating atrophy of the corpus callosum. e) Contrast-enhanced T1 image with multiple small
contrast-enhancing lesions (arrows). f) Large ischemic area in the lower half of the left retina (arrow) and smaller infarct in the top left quadrant
(tailed arrow).
reported a slow worsening of her gait over the past two
weeks, and two days before admission she had noticed
an obscuration in her left visual hemifield. Clinical exam-
ination revealed an additional proximal weakness of the
right leg and bilateral hypacusis. Ophthalmologic exami-
nation demonstrated extensive ischemic damage to both
retinae with corresponding visual field deficits (Figure 1f ).
Audiometry showed bilateral asymmetric low-frequency
sensorineural hearing loss. At this point SS was diagnosed
based on the presence of the clinical triad of encephalopa-
thy, visual disturbances and hearing loss, in conjunc-
tion with typical MRI findings (snowball lesions, callosal
atrophy), CSF and fundoscopic studies. Further ophthal-
mologic investigations such as fluoresceine angiography
(FAG) and optical coherence tomography were nor per-
formed at this stage.
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SS was diagnosed and immunosuppressive treat-
ment initiated. This included another IVMP pulse (5 ×
500mg) followed by oral prednisolone (4 weeks 60 mg/d;
2 weeks 50 mg/d; 2 weeks 40 mg/d; 2 weeks 30 mg/d;
3 weeks 20 mg/d; 3 weeks 15 mg/d; 3 weeks 10 mg/
d; 4 weeks 5 mg/d; 4 weeks 2.5 mg/d). IVIG were given at
monthly intervals at a dose of 2 g/kg over five consecutive
days for six months. In addition, a long-term therapy with
MM (2000 mg/d) and MTX (15 mg weekly s.c.) was initi-
ated. Under this regime no further relapse occurred. One
year after disease onset the patient was well. Her gait and
cognitive performance had markedly improved. MRI and
FAG showed no evidence of disease activity.
Conclusions
The case presented here illustrates several important
aspects of SS. To start with, skin involvement in terms
of LR has only been described in very few out of more
than 300 patients reported in the literature so far [1,11,12].
In most cases, similar to the one presented here, the
exanthema quickly resolved under immunosuppressive
therapy. In one case [11], skin biopsy showed signs
of complement-mediated damage to endothelial cells in
upper dermis capillaries, analogous to the histopatholog-
ical changes in brain biopsies of SS [9]. In combination
with the case presented here, these observations strongly
suggest that LR can be part of SS, and that SS is an impor-
tant differential diagnosis in an encephalopathic patient
with skin involvement compatible with LR.
The spectrum of differential diagnosis of LR in neu-
rological patients has been comprehensively reviewed by
Kraemer et al. [13]. In addition to Sneddon’s syndrome,
the authors mention neuropsychiatric SLE and antiphos-
pholipid antibody syndrome. To distinguish SS from these
differential diagnoses can be a challenge, especially if only
encephalopathy is present. In our case, the typical find-
ings on MRI could have given an indication of the correct
diagnosis SS. Specifically, lesions located in the centre or
the roof of the corpus callosum are considered specific for
SS because they are not found in MS or Acute Dissem-
inated Encephalomyelitis [5]. In addition, a reduced vol-
ume of the corpus callosum as well as meningeal contrast
enhancement are more frequently encountered in SS than
MS [5,7]. Although it is currently less clear how well other
differential diagnoses such as SLE and CNS vasculitis can
be distinguished from SS by these criteria, the above MRI
findings should always prompt further diagnostic proce-
dures including FAG, which frequently reveals subclinical
involvement of the retina in SS, a finding that can strongly
support the diagnosis [12].
The notion of skin involvement in SS is not only rel-
evant for clinical purposes, but may also contribute to
a better understanding of the relationship between SS
and other autoimmune diseases. Similarities between SS
and JDM have been emphasized by some authors [8].
Both syndromes are characterized by a widely fluctu-
ating, largely unpredictable disease activity with either
a monophasic or polycyclic clinical course. Moreover,
in the pathogenesis of either disease, AECA have been
described [9,10]. Traditionally, it was held that, despite
these commonalities, in each disease the microvascula-
ture of a distinct set of organs was affected (i.e. brain,
retina and cochlea in SS versus skin, muscle and gas-
trointestinal tract in DM/JDM). However, several results
suggest that such a strict organ specificity does not exist.
On one hand, involvement of the brain or retina has been
documented in rare cases of JDM [14,15]. On the other
hand, in SS a histological involvement of skeletal mus-
cle can be observed [3,4], and the case presented here
in combination with the report by Turc et al. demon-
strate a skin involvement with similar features as in DM.
Altogether these findings further underline a pathogenetic
relationship between SS and DM/JDM.
The case presented here further exemplifies a therapeu-
tic dilemma that may be commonly encountered in SS.
On one hand, in the case of threatening disease activ-
ity, prompt and sustained aggressive immunosupression
is warranted to prevent severe sequelae such as demen-
tia, vision loss and hearing loss. On the other hand, every
long-term immunosuppressive therapy is likely to have
significant adverse effects, and for this reason any unnec-
essarily aggressive treatment must be avoided. In the con-
text of autoimmune disease, IVCTX pulse therapy causes
premature ovarian failure in a relatively high proportion
of premenopausal women, especially in those older than
30 years [16,17]. Various strategies of fertility preserva-
tion treatment have been evaluated, but all are associated
with a significant residual risk of infertility. In contrast,
immunosuppressive therapy with MM and MTX is not
expected to have long-term adverse effects on fertility
once therapy has been completed [18].
Given the overall severe clinical presentation in our
patient, including a tendency to relapse when taper-
ing prednisolone, most physicians would probably have
started an IVCTX pulse therapy when the diagnosis of SS
was eventually made. However, this was not wanted by the
patient and her family, primarily because they intended to
have further children. Instead, a long-term immunosup-
pressive therapy with MM and MTX was initiated, and at
the same time an IVIG pulse therapy was newly started.
Interestingly, from this point on the clinical course was
much more benign, and even relatively quick tapering of
prednisolone because of a severe Cushing’s syndrome was
tolerated well. Although it is impossible to know whether
this reflects the natural course of the disease or a thera-
peutic effect of MM/MTX and/or IVIG, our case suggests
that even in patients with an initially threatening presen-
tation of SS, disease activity can sometimes be controlled
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by immunosuppresive treatment that does not rely upon
IVCTX. Given that SS often occurs in young women
before the completion of family planning, the value of such
treatment options should be systematically compared to
the standard therapy including IVCTX.
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